In 2011, Allergan filed a new drug application with the FDA for Vilazodone, seeking approval for the treatment of MDD. However, the application was withdrawn in 2012 due to concerns about the medication's efficacy and safety.
Clinical trials are a crucial step in evaluating the safety and efficacy of a medication like MIAA-774. While specific details about the trials involving MIAA-774/Vilazodone are limited, publicly available data indicate that the medication demonstrated a moderate level of efficacy in treating MDD. miaa-774
Initial trials were conducted in the mid-2000s, with researchers assessing the compound's efficacy and safety in treating major depressive disorder (MDD) in adults. The results of these early studies showed promising outcomes, prompting further development and larger-scale trials. In 2011, Allergan filed a new drug application